Deep Neuromuscular Block for Laparoscopic Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

June 16, 2017

Primary Completion Date

February 15, 2019

Study Completion Date

April 1, 2019

Conditions
LaparoscopyAnesthesia Recovery Period
Interventions
DRUG

Sugammadex

Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.

DRUG

Neostigmine

Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.

Trial Locations (4)

3050

Melbourne Health, Parkville

The Royal Womens Hospital, Parkville

Victorian Comprehensive Cancer Centre, Parkville

3083

Northpark Private Hospital, Bundoora

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Melbourne Health

OTHER

collaborator

Peter MacCallum Cancer Centre, Australia

OTHER

collaborator

Royal Hospital For Women

OTHER

collaborator

Northpark Private Hospital

UNKNOWN

lead

University of Melbourne

OTHER